Grace Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $44.2M
- Price
- $2.10
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.69%
- Volume
- 84.3K
About
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Quick stats
Shares outstanding21.0M
Computed float17.1M
Float / shares81.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001444192
Websitehttps://www.gracetx.com
AI Summary
AI-generated1/29
minorneutralother
Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference
Grace Therapeutics announced that CEO Prashant Kohli will present at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026 in New York.
The presentation will be available on demand beginning September 11, and Kohli will be available for one-on-one investor meetings throughout the conference.
Grace's lead asset GTx-104, an IV nimodipine infusion for aneurysmal subarachnoid hemorrhage, holds FDA Orphan Drug Designation; the release's risk language reiterates a prior CRL, pending contract-manufacturing remediation and reinspection, and a potential need for additional capital.
Red flags
- Boilerplate references a prior FDA Complete Response Letter (CRL) for the GTx-104 NDA, with resubmission still pending
- FDA will not approve the NDA while the current contract manufacturer remains in unacceptable compliance status; reinspection timing is outside company control
- Company discloses a potential need for additional capital, which may not be available on acceptable terms